Ozempic to treat addiction, Walgreens closes stores, weight loss drugs for work: Pharma news roundup

October 18, 2024 10:00 AM BST | By EODHD
 Ozempic to treat addiction, Walgreens closes stores, weight loss drugs for work: Pharma news roundup
Image source: Kalkine Media
Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help reduced the rate of overdoses and intoxications for people with substance use disorders, according to a new study published Thursday in the scientific journal Addiction. Walgreens announced this week that it will close another 1,200 stores in the U.S. over the next three years. And Eli Lilly has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help get some people back to work. Check out those stories and more pharmaceutical news highlights from this week.

Ozempic and other weight loss drugs could help treat alcohol and drug addiction, study says An Ozempic needle injection pen is seen in this illustration photo in Warsaw, Poland on 03 September, 2023. - Image: NurPhoto / Contributor (Getty Images) The case that Ozempic and other GLP-1 medications could help people with substance use disorders is getting stronger. Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help people struggling with alcohol and opioid addiction, according to a new study published Thursday in the scientific journal Addiction. Read More A digital health care app is using AI scans to detect muscle loss from weight-loss drugs Noom’s new AI-powered body scan feature. - Image: Noom The psychology-focused digital health care platform Noom announced an AI-powered feature on Thursday that aims to address one of the major side effects of popular weight loss drugs: lean muscle mass loss.

Noom launched a body scan feature on their app on Thursday, in partnership with Prism Labs, that allows users to generate a 3D avatar of their body and get body composition stats — all from a 10-second video of their body taken with a smartphone. Read More Can weight loss drugs get people back to work? Eli Lilly wants to find out Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo. - Image: NurPhoto / Contributor (Getty Images) Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help get some people back to work. The pharma giant said that it is investing £279 million ($365 million) in the country’s life sciences industry to help “tackle significant health challenges.” As part of the partnership, Eli Lilly will work with the government to conduct a five-year, real-world study to look at the effectiveness of the company’s tirzepatide, the drug in Zepbound and Mounjaro. The study will also collect data on healthcare resource utilization, quality of life, and changes in participants’ employment status and sick days from work.

Read More Walgreens will close 1,200 stores as it loses billions Photo: Spencer Platt (Getty Images) Walgreens (WBA) announced Tuesday that it will close another 1,200 stores in the U.S. as it tries to stem hemorrhaging losses. The pharmacy chain, which reported a $3 billion quarterly loss, said the closures will happen over the next three years. It did not specify which stores would be shutting down but said 500 of the stores will close in its 2025 fiscal year. Read More Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says Image: NurPhoto / Contributor (Getty Images) Zealand Pharma CEO Adam Steensberg said the company is working on a next-generation weight loss drug that’s designed to work differently than those currently on the market and with the potential for fewer side effects.

Read More For the latest news, Facebook, Twitter and Instagram. View comments

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next